RenBio’s latest publication highlights the potential of DNA-based medicines for metabolic disease. In a study published in Molecular Therapy Nucleic Acids, RenBio demonstrated that delivery of ultra long-lasting GLP-1-based incretin receptor agonists using its proprietary MYO Technology™ led to sustained weight loss for up to one year from a single administration in a diet-induced obesity model. These findings support the promise of DNA-based therapies to provide long-lasting treatment effects and help address key challenges in chronic disease management.
Read the full article here: https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(26)00117-4